Navigation Links
NIBIB invests in quantum research

The National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health (NIH), today announced the award of more than $12 million in grants to support research and development of potentially high-impact, innovative technologies to advance health care.

The new grants will fund four investigators in developing groundbreaking technologies: disposable microchips for the diagnosis of metastatic lung cancer, a bio-artificial kidney to eliminate dialysis procedures, insulin-producing cells to treat diabetes, and nanoparticles that selectively leave the blood and bind to cancer cells to assist in removal of brain tumors.

This innovative program from the NIBIB promises to harness the power of technological discovery and team science to translate new knowledge into practical healthcare benefits for our nation, said Elias A. Zerhouni, M.D., NIH director.

The overall goal of the NIBIB Quantum Grants program is to make a profound (quantum level) advance in health care by funding research on targeted projects that will develop new technologies and modalities for the diagnosis, treatment, or prevention of disease.

We are excited to be awarding these Quantum Grants to four excellent researchers and their interdisciplinary teams, said NIBIB director Roderic I. Pettigrew, Ph.D., M.D. We look forward to watching the extraordinary results that will be achieved as these studies progress. All four of these projects have the potential to significantly improve the current practice of medicine.

Anthony Atala, M.D., Wake Forest University Health Sciences
$3.2 million (3 years)
Insulin Producing Cells from Amniotic Stem Cells for Diabetes Therapy

Diabetes impacts the individuals afflicted and society as a whole due to the significant complications associated with using existing insulin treatment strategies. The aim of this project is to develop a new source of insulin secreting cells as a replacement strategy for treating diabetes. Transplantation of pancreatic islets to restore insulin production is promising; however, the donor pancreata are in short supply and do not meet medical needs. The development of these tissue engineered islets will provide a new source of insulin-producing cells and help realize the full potential of cell therapy for diabetes.

Raoul Kopelman, Ph.D., University of Michigan at Ann Arbor
$2.6 million (3 years)
Nanoparticle Enabled Intraoperative Imaging and Therapy

Brain cancer is one of the most lethal forms of cancer, and is diagnosed in over 43,000 new patients each year. The goal of this project is to improve surgical resection and treatment options for brain cancer patients. Dr. Kopelman and his team will develop nanoparticles that selectively leave the blood and bind to cancer cells. These nanoparticles will aid in the visualization of tumors to allow for maximal surgical resection of tumor mass and also facilitate nonsurgical destruction of the residual cancer cells that are remote or extend from the tumor mass. This may achieve significant improvement in treatment of brain tumors.

Shuvo Roy, Ph.D., Cleveland Clinic Lerner College of Medicine-CWRU
$3.2 million (3 years)
Miniaturized Implantable Renal Assist Device for Total Renal Replacement Therapy

End stage renal disease is a significant global health problem. Donor kidneys for transplantation are in short supply, with dialysis and filtration as the only alternative treatment. This investigator and his team will develop a miniaturized, implantable, and self-regulating bio-artificial kidney that takes the dialysis machinery and integrates it into a miniaturized implantable device. The successful development of this bio-artificial kidney would provide an alternative to the majority of the dialysis procedures performed annually in the U.S.

Mehmet Toner, Ph.D., Massachusetts General Hospital
$3.4 million (3 years)
Point-of-Care Microfluidics in Lung Cancer

The goal of this project is to develop a point-of-care microchip device that can determine the type, severity, and aggressiveness of a wide range of cancers by detecting tumor cells that are circulating in the blood stream. Dr. Toner and his team will develop a new disposable microchip technology capable of separating specific circulating tumor cells from whole human blood at concentrations as low as one in a billion. Detecting the presence of these tumor cells at such low concentrations enables earlier intervention in the treatment of metastatic lung cancer, which remains the leading cause of cancer death in the U.S. This point of care test can potentially transform patient care through early molecular diagnosis of lung cancer and identification of new biomarkers with which to track disease progression.


Contact: Cheryl Fee
NIH/National Institute of Biomedical Imaging & Bioengineering

Related biology news :

1. Canadas new government invests $200M in the fight against the mountain pine beetle
2. Quantum Dots Research Leads to New Knowledge about Protein Binding in Plants
3. Quantum dots provide a faster, more sensitive method for detecting respiratory viral infections
4. Method slashes quantum dot costs by 80 percent
5. New nanosensor uses quantum dots to detect DNA
6. Connect the Quantum Dots
7. Quantum dots reviewed -- Could these nanoparticles hold the cure to cancer?
8. First Quantum Grant to fund stem cell repair of damage from stroke
9. Protein enables discovery of quantum effect in photosynthesis
10. Researchers discover way to make cells in the eye sensitive to light
11. Columbia research lifts major hurdle to gene therapy for cancer
Post Your Comments:
(Date:10/8/2015)... NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... announces that revenues for the three months ended ... $113,00 for the three months ended June 30, ... 30, 2015 were approximately $520,000.      ...
(Date:10/5/2015)... ) releases the following ... NXTD ), a biometric authentication company focused on the ... ) releases the following market and company update ... authentication company focused on the growing mobile commerce market. ... ) releases the following market and company update ...
(Date:9/30/2015)... global glucose monitoring device and diabetes management market is valued ... on the industry from Kalorama Information. Sales in the traditional glucose ... continuous glucose monitoring and sensor segment, according to the healthcare ... in its latest report, The Global Glucose Monitoring Market ... , ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... ... October 13, 2015 , ... SonaCare Medical, LLC, ... that it received de novo clearance from the U.S. Food and Drug Administration ... of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device ...
(Date:10/12/2015)... and BRUSSELS , Oct. 12, 2015 /PRNewswire/ ... today presented additional findings from an exploratory sub-study of the ... were presented today in an oral plenary session at the ... Meeting in Seattle . 2 ... The small exploratory sub-study data showed that, at month ...
(Date:10/12/2015)... Oct. 12, 2015  Rebiotix Inc. today announced ... designated its lead Microbiota Restoration Therapy (MRT) RBX2660 ... recurrent Clostridium difficile (C diff) infection, ... causes 29,000 deaths in the U.S. annually. 1 ... that was founded to revolutionize the treatment of ...
(Date:10/12/2015)...  Patara Pharma, a clinical-stage biotechnology company developing ... conditions, today announced the closing of a $26 ... the close of its sale of preferred stock, ... Agreement with Silicon Valley Bank whereby the Company ... use the funds from the financing to evaluate ...
Breaking Biology Technology: